MUC1 aptamer-capped mesoporous silica nanoparticles for controlled drug delivery and radio-imaging applications
Autores de CIPF
Participantes ajenos a CIPF
- Pascual, L
- Cerqueira-Coutinho, C
- de Luis, B
- Bernardes, ES
- Albernaz, MS
- Missailidis, S
- Santos-Oliveira, R
Grupos de Investigación
Abstract
Mucin 1 (MUC1) is a cell surface protein overexpressed in breast cancer. Mesoporous silica nanoparticles (MSNs) loaded with safranin O, functionalized with aminopropyl groups and gated with the negatively charged MUC1 aptamer have been prepared (S1-apMUC1) for specific targeting and cargo release in tumoral versus non-tumoral cells. Confocal microscopy studies showed that the S1-apMUC1 nanoparticles were internalized in MDA-MB-231 breast cancer cells that overexpress MUC1 receptor with subsequent pore opening and cargo release. Interestingly, the MCF-10-A non-tumorigenic breast epithelial cell line that do not overexpress MUC1, showed reduced (S1-apMUC1) internalization. Negligible internalization was also found for S1-ap nanoparticles that contained a scrambled DNA sequence as gatekeeper. S2-apMUC1 nanoparticles (similar to S1-apMUC1 but loaded with doxorubicin) internalized in MDA-MB-231 cells and induced a remarkable reduction in cell viability. Moreover, S1-apMUC1 nanoparticles radio-labeled with Tc-99m (S1-apMUC1-Tc) showed a remarkable tumor targeting in in vivo studies with MDA-MB-231 tumor-bearing Balb/c mice. (C) 2017 Elsevier Inc. All rights reserved.
Datos de la publicación
- ISSN/ISSNe:
- 1549-9634, 1549-9642
- Tipo:
- Article
- Páginas:
- 2495-2505
- PubMed:
- 28842375
NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE ELSEVIER SCIENCE BV
Citas Recibidas en Web of Science: 90
Documentos
- No hay documentos
Filiaciones
Keywords
- Radiopharmaceuticals; Nanotechnology; Oncology; Mesoporous silica nanoparticles
Proyectos asociados
Exploiting Protein Complexes that induce Cell-death
Investigador Principal: MARIA MAR ORZÁEZ CALATAYUD
COMMISSION OF EUROPEAN COMMUNITIES . 2016
Red de Transtornos Adictivos
Investigador Principal: CONSUELO GUERRI SIRERA
INSTITUTO DE SALUD CARLOS III . 2017